4 Nov
2020

Amgen suffers another setback in antibody IP war

The EPO has invalidated claims from Amgen's PCSK9 genus patent ahead of a crucial CAFC case on antibody patents to be heard next month.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth